Johnson & Johnson
JNJ-
Johnson & Johnson added 0.1% to $157.57 after the company reported slightly better-than-expected quarterly results.
Revenue in the third quarter increased 6.8% to $21.3 billion from $19.99 billion and net earnings was flat at $4.3 billion and diluted earnings per share edged up 4% to $1.69 from $1.62 a year ago.
Sales in the U.S. increased 11.1% to $12 billion from $10.8 billion and international sales rose 1.6% to $9.3 billion from $9.2 billion a year ago.
The company revised higher its estimate of non-GAAP annual sales growth estimate to between 8.5% and 9.0% from the previous estimate between 8.0% and 8.5%.
Oct 17, 2023 -
Johnson & Johnson the pharmaceuticals and consumer products maker, said first quarter revenue increased 5.6% to $24.75 billion.
The company swung to a net loss of $68 million from a profit of $5.2 billion and diluted earnings per share swung to ($0.03) from $1.93 a year ago.
Adjusted earnings, which excludes special items and amortization expenses, fell 0.9% to $7.06 billion from $7.2 billion and adjusted diluted earnings per share inched up to $2.68 from $2.67 a year ago.
Apr 18, 2023 -
Johnson & Johnson said revenue in the December quarter fell 4% to $23.7 billion and net earnings fell 26% to $3.52 billion or $1.33 from $4.74 billion or $1.77 per share in the previous year.
Jan 24, 2023
|
|
| |
|
| Trading Volume | 155,788 |
|
|
164.59 - 144.51 |
| Market Cap Full | $ 395.9B |
Quarterly +
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Q1 | -0.3% | 0.9% | -12.3% | 3.6% |
| Q2 | - | -7.7% | 6.7% | 0.2% |
| Q3 | - | 3.8% | -5.8% | -8.6% |
| Q4 | - | -3.3% | 1% | 8.8% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2025 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.3 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| 1.4 | 1.6 | -2 | -5.8 | -1.7 | -0.6 | 8.6 | 3.8 | - | - | - | - |
| 2023 | |||||||||||
| -7.5 | -6.2 | 1.1 | 5.7 | -5.2 | 6.6 | 1.3 | -3.5 | -3.7 | -4.8 | 4.3 | 1.4 |
| 2022 | |||||||||||
| 0.7 | -5 | 8.3 | 1.8 | -0.5 | -1.1 | -1.7 | -7.6 | 0.6 | 6.5 | 3 | -0.8 |
| 2021 | |||||||||||
| 3.7 | -2.9 | 3.7 | -1 | 4 | -2.7 | 4.5 | 0.5 | -6.7 | 0.9 | -4.3 | 9.7 |
| 2020 | |||||||||||
| 2.9 | -11.3 | -1.2 | 14.4 | -0.9 | -5.5 | 3.7 | 5.3 | -3 | -7.9 | 5.5 | 8.8 |
EPS
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Q1 | -0 | 1.9 | 2.3 | 2.2 |
| Q2 | 2 | 1.8 | 2.4 | 1.4 |
| Q3 | 10.2 | 1.7 | 1.4 | 1.3 |
| Q4 | 0 | 1.3 | 1.8 | 0.7 |
| A | 12.14 | 6.7 | 7.8 | 5.5 |